The complications of chronic kidney disease (CKD) are dyslipidaemia, hyperkalaemia, metabolic acidosis, anaemia, and bone and mineral disorders. Dyslipidaemia may be treated with low-density lipoprotein-lowering agents. Statins are ineffective in stages 4 and 5 CKD, but are indicated for preventing the progression of disease in the earlier stages. Chronic acidosis has recently been shown to be a risk factor in the progression of CKD renal dysfunction. Therefore, treatment is mandatory. Practically, this should consist of 1 - 2 heaped teaspoons of sodium bicarbonate 2 - 3 times per day, which is an inexpensive and safe therapy that does not raise the blood pressure in spite of the increased sodium level. Target levels of haemoglobin, according to international guidelines, are between 10 g/dL and 12 g/dL. The serum phosphate level is raised in stage 4 CKD, and especially in stage 5 CKD, which is associated with coronary carotid and other vascular calcifications and may result in ischaemic heart disease, myocardial infarction and stroke. A raised parathyroid hormone level (secondary hyperparathyroidism) is also a major risk factor for cardiovascular disease and is associated with increased hypertension and resistance to the treatment of CKD-associated anaemia.

**Dyslipidaemia**
Chronic kidney disease (CKD) is associated with alterations in lipoprotein structure and function, including:

- reduced high-density lipoprotein cholesterol
- increased intermediate-density lipoprotein
- increased proatherogenic lipid particles.

**Significance of dyslipidaemia control**
- Successful treatment of dyslipidaemia is known to lower cardiovascular disease (CVD) risk and should also retard the decline of kidney function.
- Since statins have been shown to decrease urinary protein or albumin excretion, they are recommended for CKD with proteinuria.
- Remarks on statin use in stages 3 - 5 CKD are given in Table 1.
- Concurrent use of statins and fibrates increases the risk of rhabdomyolysis.

**Target for low-density lipoprotein cholesterol**
- The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend the following for dyslipidaemia therapy in CKD: in cases of low-density lipoprotein cholesterol (LDL-C) <3.5 mmol/L, the first step is lifestyle modification; in cases of LDL-C >3.5 mmol/L, drug therapy should be contemplated in addition to lifestyle modification, including diet therapy, weight control and exercise.
- It is essential that LDL-C be lowered to ≤1.8 mmol/L.

**KDOQI guidelines for cholesterol lowering in CKD patients (2013):**
- Patients >50 years of age should receive a statin.
- Patients 18 - 49 years of age should receive a statin if another comorbidity is present.
- Kidney transplant recipients should receive a statin.

**Treatment of hyperkalaemia and metabolic acidosis**

**Hyperkalaemia**
- As CKD progresses in stage, acidosis and hyperkalaemia are observed.
- Hyperkalaemia is defined as a serum potassium level ≥5.5 mmol/L. Hyperkalaemia >7 mmol/L may potentially cause cardiac arrest; such cases should be treated as emergencies.
- If severe hyperkalaemia is observed, despite the absence of reduced kidney function, pseudohyperkalaemia, an artefact due to haemolysis of the blood specimen, should be considered.
- Hyperkalaemia is a risk factor for arrhythmias. In cases of severe hyperkalaemia, emergency levels should be confirmed by ECG abnormalities such as tenting T-waves, prolongation of PQ-times, followed by disappearance of the P-wave and widening of the QRS complex. Patients with life-threatening ECG findings, bradycardia and hypotension should be treated promptly, followed by treatment in conjunction with a nephrologist.
- Drug-induced hyperkalaemia in CKD is mostly caused by renin-angiotensin-aldosterone inhibitors such as ACE inhibitors, angiotensin II receptor blockers (ARBs) and spironolactone or excessive intake of potassium-containing foods. Other causes include the administration of β-blockers, digoxin, non-steroidal anti-inflammatory drugs (NSAIDs), trimethoprim or penicillin.
- CKD caused by diabetic nephropathy may be associated with hyporeninaemic hypoaldosteronism, which may cause hyperkalaemia despite relatively well-preserved kidney function. This is known as type IV renal tubular acidosis.

**Emergency treatment**
- The first step is to stabilise the myocardium. The intravenous administration of calcium gluconate does not change plasma potassium, but transiently improves the ECG. The administration of calcium gluconate 20 mL intravenously over 1 minute can...
be repeated if there is no improvement in the ECG within 3 - 5 minutes.

- The second step is to shift the potassium from the extracellular to the intracellular compartment to try to rapidly decrease the serum potassium level. This can be done in three different ways:
  - **Intravenous insulin combined with glucose.** Administer 10 U short-acting insulin combined with 50 mL of 50% dextrose as a bolus, followed by an intravenous infusion of 5% dextrose to prevent hypoglycaemia.
  - **β2-agonist.** Administer 20 mg salbutamol, a β2-agonist, by inhalation over 10 minutes, with onset of action approximately 30 minutes. (This is not usually required.)
  - **Sodium bicarbonate in CKD patients who are not yet on dialysis.** Bicarbonate administration can lower serum potassium by enhancing renal potassium excretion. The effect is very slow and not of use in an acute situation unless the patient has severe metabolic acidosis that needs bicarbonate treatment.

- Once the previous temporary measures have been performed, further interventions are undertaken to remove potassium from the body.
  - **Loop diuretics are only successful in patients with adequate kidney function.**
  - **The resin exchanger sodium polystyrene sulphonate (Kexelate) removes potassium from the blood into the gut in exchange for an equal amount of sodium. It is slow acting and the plasma potassium only starts decreasing within 1 - 2 hours. It can be given orally or as a retention enema. The amount given varies from 30 g to 60 g. This can be repeated, but tends to cause constipation.**
  - **Haemodialysis is the treatment of choice for patients with advanced CKD and severe hyperkalaemia.**

**Prevention**

- **Dietary counselling on potassium restriction.**
- **Avoid medications that interfere with renal excretion of potassium, e.g. potassium-sparing diuretics, NSAIDs, ACE inhibitors, ARBs.**
- **Avoid drugs that interfere with potassium shifts from the intracellular to the extracellular compartments, e.g. non-selective β-blockers.**
- **In selected patients with sufficient residual kidney function treatment with a loop diuretic may be used to stimulate urinary potassium excretion with a loop diuretic may be used to stimulate urinary potassium excretion.**

**Metabolic acidosis**

Metabolic acidosis is characterised by:
- low arterial blood pH (acidaemia) (<7.35)
- reduced serum HCO3- concentration
- decreased pCO2 (from respiratory compensation).

**Systemic effects**

Metabolic acidosis may lead to a variety of changes in tissues and organs, e.g.:
- cardiovascular changes such as tachycardia, bradycardia, hypotension and cardiac failure
- life-threatening hyperkalaemia
- nausea, vomiting and abdominal pain
- confusion, with depression of the central nervous system.

The associated symptoms and signs will depend on the rate and magnitude of fall in the pH and of the underlying pathology.

---

**Table 1. Drugs for dyslipidaemia available in South Africa and cautionary remarks regarding their use in CKD**

<table>
<thead>
<tr>
<th>Class</th>
<th>Generic name</th>
<th>Characteristics</th>
<th>Use in low GFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme inhibitors (statins)</td>
<td>Pravastatin, Simvastatin, Fluvastatin, Atorvastatin, Rosuvastatin</td>
<td>Inhibits cholesterol production in the liver</td>
<td>Main excretory route is the bile duct, i.e. it can be used in kidney damage (pravastatin is excreted mainly in the urine) Rhabdomyolysis may occur, although there is a low incidence in CKD. In stages 3 and higher CKD, careful follow-up is necessary. Cyclosporine, which is often used in resistant nephrotic syndrome, may have adverse effects if used simultaneously.</td>
</tr>
<tr>
<td>Anion exchange resins</td>
<td>Cholestyramine, Colestamide</td>
<td>Inhibits bile acid circulation (intestine-liver)</td>
<td>No problems</td>
</tr>
<tr>
<td>Fibrates</td>
<td>Bezaflibrate, Fenofibrate</td>
<td>Lowers TG (very effective) Increases HDL-C Rhabdomyolysis Do not use with statins</td>
<td>Do not use bezafibrate or fenofibrate in kidney failure or dialysis patients Do not use for stages 4 and 5 CKD</td>
</tr>
<tr>
<td>Nicotinic acids</td>
<td>Bezafibrate, Fenofibrate</td>
<td>Lowers TG Lowers Lp (a) Rash on face</td>
<td>No problems</td>
</tr>
<tr>
<td>Others</td>
<td>Eicosapentaenoic acid Ezetimibe</td>
<td>Lowers TG Antiplatelet function: anti-atherosclerosis Prevents absorption of cholesterol</td>
<td>No problems</td>
</tr>
</tbody>
</table>

TC = total cholesterol; TG = triglyceride; HDL-C = high-density lipoprotein cholesterol; LPL = lipoprotein lipase; Lp (a) = lipoprotein (a); GFR = glomerular filtration rate; ECG = electrocardiogram.
**Uræmic acidosis**

Metabolic acidosis occurs in renal failure owing to a decreased ability to excrete H⁺ or an inability to produce ammonia.

In the early stages of CKD (GFR <40 mL/min), metabolic acidosis with a normal anion gap (AG) may become evident. As CKD progresses (GFR <20 mL/min), a high AG metabolic acidosis may result.

In advanced CKD, an increased AG is typical owing to the presence of retained acids such as sulphates, phosphates, urate and hippurate.

**Treatment principles**

Patients with metabolic acidosis are often very ill and their condition tends to deteriorate rapidly.

The routine administration of sodium bicarbonate is controversial, although it needs to be done to correct severe acidosis.

The potential complications of sodium bicarbonate administration include volume overload, especially in patients with renal or cardiac function impairment, hypernatraemia, hypokalaemia, hypocalcaemia and alkalosis.

The amount of bicarbonate required (mmol) can be estimated as follows:

\[ \text{target plasma } \text{HCO}_3^- \text{ (mmol/L)} = \text{current plasma } \text{HCO}_3^- \text{ (mmol/L)} \times 40\% \text{ body weight (kg)}. \]

**Anaemia in CKD**

Anaemia is the most common complication of CKD and is associated with greatly reduced quality of life. Successful treatment of anaemia in renal disease may reduce the decline of kidney function. The target haemoglobin levels are 10 - 12 g/dL when treating anaemia in CKD. The treatment is costly and therefore rational consideration is mandatory.

**Renal anaemia**

Renal anaemia is typically normochromic normocytic. It is caused mainly by the impaired production of erythropoietin by the kidney and partly by uræmic toxins. Other causes that may play a role in CKD, especially in dialysis patients, are:

- erythropoietin resistance (most significant)
- bone marrow toxins (none has been isolated yet)
- bone marrow fibrosis, secondary to hyperparathyroidism
- ongoing inflammatory processes, e.g. untreated infections
- haematinic deficiency (iron, folate and vitamin B₁₂)
- increased red cell destruction
- abnormal red cell membranes, causing increased osmotic fragility
- increased blood loss from occult gastrointestinal bleeding and blood sampling and during haemodialysis
- ACE inhibition.

Erythropoietin is a glycoprotein hormone that stimulates red cell production by binding to erythropoietin receptors, located on early erythroid progenitor cells in the bone marrow.

The binding of erythropoietin to these progenitor cells saves them from apoptosis and therefore permits cell division and maturation into red cells. In CKD, the erythropoietin levels may be normal, but inadequate for the degree of anaemia. The mechanisms impairing erythropoietin production in diseased kidneys remain poorly understood. Inhibition of erythropoiesis by uræmic inhibitors is also possible and may contribute greatly to the anaemia of CKD; such factors have not been identified. Dialysis can improve renal anaemia and the efficacy of erythropoietin-stimulating agents. Patients with renal disease may develop chronic infections and other chronic diseases. Chronic disease contributes to anaemia in such cases. The anaemia of chronic disease is mediated by inflammatory cytokines through the inhibition of erythropoietin production and efficacy and reduced iron availability.

Hepcidin is the key mediator of iron metabolism. In inflammatory states hepcidin blocks iron absorption in the gut and promotes iron sequestration in macrophages.

**Other causes**

Anaemia associated with CKD is most likely renal anaemia; however, the differential for other diseases must be considered true for stages 1 - 3 CKD.

The evaluation of anaemia in CKD patients should include a complete blood count with red cell indices (mean corpuscular haemoglobin concentration, mean corpuscular volume). Renal anaemia is usually normochromic and normocytic. Vitamin B₁₂ and folate deficiency may lead to macrocytosis, while iron deficiency or inherited disorders of haemoglobin may produce microcytosis. Iron studies should be performed to assess the level of iron in tissue stores or the adequacy of iron supply for erythropoiesis.

Anaemia may signify the presence of malnutrition or systemic illness. It is an independent risk factor for hospitalisation, CVD and mortality. ACE inhibitors can exacerbate anaemia.

**Treatment of anaemia protects the heart**

Anaemia exacerbates heart failure. Treatment of anaemia is beneficial for life expectancy and can also improve the prognosis of CVD. The quality of life is improved for those with a haemoglobin level within the target range.

**Target level of haemoglobin**

The Kidney Disease Improving Global Outcome (KDIGO) guidelines state that the haemoglobin level should range from 10.0 g/dL to 12 g/dL in CKD patients on dialysis. Pre-dialysis levels should be at 10 g/dL.

**Role-sharing between nephrologists and primary care physicians**

Early referral to a nephrologist is advisable. Once the treatment strategy has been decided, nephrologists and primary care physicians continue management in partnership.

**Evaluation of iron deficiency**

Evaluation of the iron deficit and correct iron supply is important in the treatment of anaemia. Anaemia may improve with the administration of iron supplements, even when the patient is not apparently iron deficient, as the use of recombinant erythropoietin may cause relative iron deficiency.

The KDOQI guidelines for recombinant human erythropoietin in CKD are:

- serum ferritin >100 ng/mL before dialysis
- serum ferritin >200 ng/mL in dialysis patients
- transferrin saturation >20%.

Iron can be given either intravenously or orally. Intravenous iron is more efficacious, especially for dialysis patients and those on erythropoietin treatment.

**Use of exogenous erythropoietins**

There are currently a number of erythropoietin-stimulating agents available, including older, shorter-acting drugs and new, longer-acting ones. The appropriate agent and dose depend on a number of factors,
including cost, efficacy and convenience. As these drugs are expensive and have side-effects, their management is best left to a nephrologist.

**Bone and mineral disorders**

Hyperphosphataemia is the key abnormality that sets off a cascade of metabolic events, resulting in bone mineral density of CKD.

Phosphate is retained as renal function deteriorates – much the same as creatinine is retained. This retention becomes obvious as stage 3b CKD is reached. It will progressively worsen as end-stage is approached and must be lowered to within normal limits.

A high phosphate diet stimulates osteocytes to produce fibroblast growth factor 23 which, in turn, inhibits the hydroxylation of vitamin D to active 1,25 vitamin D₃. Without vitamin D₃, calcium absorption and bone remodelling are decreased. The resultant hypocalcaemia is a major stimulus for parathyroid hormone (PTH) release, with the consequent development of renal bone disease. Serum alkaline phosphatase is a marker of increased bone turnover. Therefore, high blood levels show PTH activity.

Of note, both hyperphosphataemia and vitamin D₃ deficiency result in increased PTH secretion.

Initially the stimulus for PTH secretion may be controlled by increasing the serum calcium, reducing the phosphate levels in the blood and prescribing vitamin D₃. This is the secondary hyperparathyroidism stage (Table 2). However, with time and uncontrolled, prolonged stimulation of PTH secretion, the parathyroid hormones become autonomous and the stage of autonomous hyperparathyroidism is reached (Table 3). Parathyroidectomy may now be necessary or expensive calcimimetic drugs must be administered to try to restore the disordered metabolic environment.

There is uncertainty about the interpretation of vitamin D₃ level measurements. If they are to be measured, then 25-OH-vitamin D₃ levels are recommended for assessment.

**Table 2. Diagnosis of secondary hyperparathyroidism***

<table>
<thead>
<tr>
<th>Serum biochemistry</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium</td>
<td>Below or low normal range</td>
</tr>
<tr>
<td>Phosphate</td>
<td>High</td>
</tr>
</tbody>
</table>

*PTH 2 - 9 times the normal range (check with the laboratory which assay and normal range) and low vitamin D₃ levels: measure 25-OH-vitamin D₃.

**Table 3. Autonomous hyperparathyroidism***

<table>
<thead>
<tr>
<th>Serum biochemistry</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium</td>
<td>Higher or high normal range</td>
</tr>
<tr>
<td>Phosphate</td>
<td>High</td>
</tr>
</tbody>
</table>

*PTH >2 - 9 times the normal range (check with the laboratory which assay and normal range).

**Table 4. Steps for therapy**

<table>
<thead>
<tr>
<th>Steps</th>
<th>Stages 3 - 4 CKD</th>
<th>Stages 5 - 5d CKD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower the serum phosphate</td>
<td>Calcium carbonate or non-calcium-containing phosphate binders, e.g. lanthanum carbonate or sevelamer carbonate</td>
<td>Calcium carbonate or non-calcium-containing phosphate binders, e.g. lanthanum carbonate or sevelamer carbonate</td>
</tr>
<tr>
<td>Increase the serum calcium</td>
<td>First administer calcium carbonate, then vitamin D₃</td>
<td>First administer calcium carbonate, then vitamin D₃</td>
</tr>
</tbody>
</table>

**Table 5. Follow-up blood measurements**

<table>
<thead>
<tr>
<th>Stage CKD</th>
<th>3-monthly</th>
<th>6-monthly</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Calcium and phosphate levels</td>
<td>Calcium, phosphate and alkaline phosphatase levels</td>
</tr>
<tr>
<td>4</td>
<td>Calcium, phosphate and alkaline phosphatase levels</td>
<td>PTH levels</td>
</tr>
<tr>
<td>5</td>
<td>Calcium, phosphate and alkaline phosphatase levels</td>
<td>PTH levels</td>
</tr>
</tbody>
</table>